Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bryostatin-1 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- BryoLogyx
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of bryostatin-1, a macrocyclic lactone that modulates protein kinase C (PKC), and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. This combination was developed based on preclinical evidence suggesting synergistic antitumor effects. The sequence of administration appears critical, with paclitaxel followed by bryostatin-1 showing better efficacy than the reverse order. The combination has been studied in various cancer types including non-small cell lung cancer, pancreatic cancer, prostate cancer, and esophageal/stomach cancer, though clinical trials have shown limited efficacy and notable toxicity, particularly myalgia.
02
Targets
PKC (Protein kinase C family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bryostatin-1 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bryostatin-1 + paclitaxel.